Trial Profile

Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifabotuzumab (Primary)
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Humanigen

Most Recent Events

07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
16 Nov 2015 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
13 Nov 2015 As per a KaloBios media release, company will discontinue two development programs, which consists of this and other Phase 1 trial (see profile 256869).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com